Literature DB >> 19895898

Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes.

Xiugong Gao1, Radharaman Ray, Yan Xiao, Keiko Ishida, Prabhati Ray.   

Abstract

BACKGROUND: Sulfur mustard (SM) inhalation causes apoptosis and death of airway epithelial cells as well as inflammation in the airway. Efficient clearance of the cell debris by alveolar macrophages is necessitated to reduce the inflammation. Macrolide antibiotics have been reported to have anti-inflammatory properties by modulating the production of proinflammatory cytokines and mediators, and by improving macrophage functions. The present study investigated the effects of four commonly used macrolide antibiotics, namely azithromycin, clarithromycin, erythromycin, and roxithromycin, on chemotactic and phagocytotic function and on inflammatory cytokines/mediators production in vitro in SM-exposed monocyte THP-1 cells.
RESULTS: Chemotaxis and phagocytosis of the monocytes reduced upon exposure to 10microM SM (8.1% and 17.5%, respectively) were restored by treatment with 10microM of any of the four macrolides. Overexpression of inflammatory cytokines following SM exposure was decreased by 50-70% with macrolide treatment. Similarly, exaggerated iNOS expression and nitric oxide (NO) production induced by SM exposure was largely inhibited by treatment with macrolides.
CONCLUSION: The data demonstrate that macrolide antibiotics were effective in improving the degenerated chemotactic and phagocytotic functions of monocytes following SM exposure, and in reducing SM-induced overproduction of proinflammatory cytokines and mediators. Thus, treatment with macrolide antibiotics may lead to improved clearance of apoptotic material in the airway and ultimately result in reduced airway inflammation and injury caused by SM inhalation, suggesting that macrolide antibiotics may serve as potential vesicant respiratory therapeutics. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895898     DOI: 10.1016/j.pupt.2009.10.010

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  14 in total

Review 1.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

3.  Inflammatory effects of inhaled sulfur mustard in rat lung.

Authors:  Rama Malaviya; Vasanthi R Sunil; Jessica Cervelli; Dana R Anderson; Wesley W Holmes; Michele L Conti; Ronald E Gordon; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2010-07-24       Impact factor: 4.219

4.  Functional and inflammatory alterations in the lung following exposure of rats to nitrogen mustard.

Authors:  Vasanthi R Sunil; Kinal J Patel; Jianliang Shen; David Reimer; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2010-09-29       Impact factor: 4.219

Review 5.  Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity.

Authors:  Barry Weinberger; Jeffrey D Laskin; Vasanthi R Sunil; Patrick J Sinko; Diane E Heck; Debra L Laskin
Journal:  Pulm Pharmacol Ther       Date:  2010-09-17       Impact factor: 3.410

Review 6.  Mustard vesicant-induced lung injury: Advances in therapy.

Authors:  Barry Weinberger; Rama Malaviya; Vasanthi R Sunil; Alessandro Venosa; Diane E Heck; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-19       Impact factor: 4.219

7.  Treatment for sulfur mustard lung injuries; new therapeutic approaches from acute to chronic phase.

Authors:  Zohreh Poursaleh; Ali Amini Harandi; Ensieh Vahedi; Mostafa Ghanei
Journal:  Daru       Date:  2012-09-10       Impact factor: 3.117

8.  Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury.

Authors:  Bei Zhang; William M Bailey; Timothy J Kopper; Michael B Orr; David J Feola; John C Gensel
Journal:  J Neuroinflammation       Date:  2015-11-24       Impact factor: 8.322

9.  Impaired macrophage phagocytosis of bacteria in severe asthma.

Authors:  Zhike Liang; Qingling Zhang; Catherine Mr Thomas; Kirandeep K Chana; David Gibeon; Peter J Barnes; Kian Fan Chung; Pankaj K Bhavsar; Louise E Donnelly
Journal:  Respir Res       Date:  2014-06-27

10.  Metabolomics diagnostic approach to mustard airway diseases: a preliminary study.

Authors:  BiBi Fatemeh Nobakht Mothlagh Ghoochani; Rasoul Aliannejad; Afsaneh Arefi Oskouie; Mostafa Rezaei-Tavirani; Shiva Kalantari; Mohammad Taghi Naseri; Alireza Akbarzadeh Baghban; Hadi Parastar; Ghazaleh Aliakbarzadeh
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.